Metachromatic leukodystrophy (MLD) is a rare genetic disorder characterized by the accumulation of sulfatides, fatty substances that damage the myelin sheath, which insulates nerve fibers in the central and peripheral nervous systems. This damage impairs the functioning of the nervous system and is caused by mutations in the ARSA gene, leading to a deficiency of the enzyme arylsulfatase A. MLD presents in three forms based on the age of onset: late-infantile, juvenile, and adult, with symptoms ranging from developmental delays and motor dysfunction to behavioral and cognitive decline.

The symptoms of metachromatic leukodystrophy (MLD) vary depending on the type and age of onset: Late-Infantile MLD (12-24 months): Developmental delays and regression of motor skills, Muscle weakness and wasting, Hypotonia, Ataxia, Seizures, Vision and hearing loss, Behavioral changes. Juvenile MLD (4-12 years): Decline in school performance and cognitive abilities, Behavioral changes, Motor difficulties, Speech and language regression, Seizures, Peripheral neuropathy. Adult MLD (Late adolescence/adulthood): Behavioral and psychiatric issues, Cognitive decline, Motor symptoms, Peripheral neuropathy, Speech difficulties, Incontinence. General Symptoms: Progressive loss of motor and cognitive functions, Spasticity, Difficulty swallowing and feeding problems, Involuntary muscle movements (dystonia), Decline in vision and hearing.

Metachromatic leukodystrophy (MLD) is caused by mutations in the ARSA gene, which provides instructions for producing the enzyme arylsulfatase A. This enzyme is essential for breaking down sulfatides, a type of fatty substance, in the lysosomes of cells. When there are mutations in the ARSA gene, arylsulfatase A is either deficient or malfunctioning, leading to the accumulation of sulfatides in the nervous system. In rare cases, MLD can also be caused by mutations in the PSAP gene.

Diagnosing MLD involves several steps: • Clinical Evaluation: Medical History and Physical Examination. • Laboratory Tests: Enzyme Activity Test (measuring arylsulfatase A), Urine Test (elevated sulfatides). • Genetic Testing: DNA Analysis aimed at ARSA gene, Carrier Testing. • Imaging Studies: MRI to detect changes in white matter. • Electrophysiological Studies: Nerve Conduction Studies.

Currently, there is no cure for metachromatic leukodystrophy (MLD), but various treatments aim to manage symptoms and slow disease progression. The treatment approaches include: • Enzyme Replacement Therapy (ERT): This experimental treatment aims to replace the deficient enzyme arylsulfatase A. • Gene Therapy: Research is ongoing into gene therapy approaches that could correct the underlying genetic defect.